Parkinson's disease (PD) is the second most common neurodegenerative disease with an incidence of 1 in 100 people over 50 years of age. Most common symptoms seen in this population are related to the motor system, but with increased awareness of non-motor symptoms (NMS),such as anxiety, depression, stress, fatigue, behavioral changes, sensory and sleep abnormalities are also being reported frequently, including anxiety, depression, stress, fatigue, behavioral changes, sensory and sleep abnormalities have been reported [
]. These symptoms need special consideration as these symptoms may exaggerate the motor symptoms. We are grateful to Espay et al. [
- Timmer M.H.
- van Beek M.H.
- Bloem B.R.
- Esselink R.A.
What a neurologist should know about depression in Parkinson’s disease.
Pract. Neurol. 2017; 17: 359-368https://doi.org/10.1136/practneurol-2017-001650
] for their recently published article entitled, ‘Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease’ in Journal of the neurological sciences. They found that motor symptoms can get exaggerated with depression in these patients, dopamine agonist (DA) have no beneficial effect in the treatment of depression, and need of an additional medication class to treat depression in this population. This research is a significant contribution to science literature.
- Espay A.J.
- Foster E.D.
- Coffey C.S.
- Uribe L.
- Caspell-Garcia C.J.
- Weintraub D.
- Parkinson’s Progression Markers Initiative
Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson’s disease.
J. Neurol. Sci. 2019; 402: 81-85https://doi.org/10.1016/j.jns.2019.05.009
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of the Neurological Sciences
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- What a neurologist should know about depression in Parkinson’s disease.Pract. Neurol. 2017; 17: 359-368https://doi.org/10.1136/practneurol-2017-001650
- Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson’s disease.J. Neurol. Sci. 2019; 402: 81-85https://doi.org/10.1016/j.jns.2019.05.009
- Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system.Brain. 2005; 128: 1314-1322https://doi.org/10.1093/brain/awh445
- Dopaminergic therapies for non-motor symptoms in Parkinson’s disease.CNS Drugs. 2017; 31: 551-570https://doi.org/10.1007/s40263-017-0450-z
- Early life stress, depression and Parkinson’s disease: a new approach.Mol. Brain. 2018; 11: 18https://doi.org/10.1186/s13041-018-0356-9
- Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis.Medicine. 2017; 96https://doi.org/10.1097/MD.0000000000006698
- A systematic review and meta-analysis of cognitive behavioral and psychodynamic therapy for depression in Parkinson’s disease patients.Neurol. Sci. 2015; 36: 833-843https://doi.org/10.1007/s10072-015-2118-0
Published online: July 09, 2019
Accepted: June 26, 2019
Received: June 22, 2019
© 2019 Elsevier B.V. All rights reserved.